The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Xeris Biopharma Holdings Inc (NASDAQ: XERS) closed at $6.96 down -1.83% from its previous closing price of $7.09. In other words, the price has decreased by -$1.83 from its previous closing price. On the day, 2.3 million shares were traded. XERS stock price reached its highest trading level at $7.24 during the session, while it also had its lowest trading level at $6.925.
Ratios:
For a deeper understanding of Xeris Biopharma Holdings Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 115.83. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.93.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $9.
Piper Sandler Downgraded its Overweight to Neutral on November 11, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 ’26 when Shannon John Patrick Jr sold 24,907 shares for $7.08 per share. The transaction valued at 176,257 led to the insider holds 2,705,346 shares of the business.
Hecht Beth sold 16,667 shares of XERS for $123,776 on Jan 02 ’26. The insider now owns 1,308,103 shares after completing the transaction at $7.43 per share. On Dec 19 ’25, another insider, JOHN H JOHNSON, who serves as the Director of the company, bought 135,402 shares for $7.22 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XERS now has a Market Capitalization of 1154833024 and an Enterprise Value of 1320889088. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.34. Its current Enterprise Value per Revenue stands at 4.963 whereas that against EBITDA is 47.114.
Stock Price History:
The Beta on a monthly basis for XERS is 0.64, which has changed by 1.1101191 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, XERS has reached a high of $10.08, while it has fallen to a 52-week low of $3.14. The 50-Day Moving Average of the stock is -8.29%, while the 200-Day Moving Average is calculated to be 9.24%.
Shares Statistics:
For the past three months, XERS has traded an average of 2.47M shares per day and 2527440 over the past ten days. A total of 165.53M shares are outstanding, with a floating share count of 155.20M. Insiders hold about 6.46% of the company’s shares, while institutions hold 59.08% stake in the company. Shares short for XERS as of 1765756800 were 15434811 with a Short Ratio of 6.25, compared to 1763078400 on 15746194. Therefore, it implies a Short% of Shares Outstanding of 15434811 and a Short% of Float of 9.67.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is $0.01, with high estimates of $0.01 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.17 and -$0.04 for the fiscal current year, implying an average EPS of $0.06. EPS for the following year is $0.31, with 2.0 analysts recommending between $0.41 and $0.22.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $81.38M this quarter.It ranges from a high estimate of $82.5M to a low estimate of $79M. As of. The current estimate, Xeris Biopharma Holdings Inc’s year-ago sales were $60.1MFor the next quarter, 6 analysts are estimating revenue of $83.23M. There is a high estimate of $86.9M for the next quarter, whereas the lowest estimate is $80.1M.
A total of 6 analysts have provided revenue estimates for XERS’s current fiscal year. The highest revenue estimate was $288.6M, while the lowest revenue estimate was $285M, resulting in an average revenue estimate of $287.42M. In the same quarter a year ago, actual revenue was $203.07MBased on 6 analysts’ estimates, the company’s revenue will be $367.52M in the next fiscal year. The high estimate is $432.3M and the low estimate is $337.9M.
